Arvinas Appoints New CMO, Elects Director
Ticker: ARVN · Form: 8-K · Filed: Jun 24, 2024 · CIK: 1655759
| Field | Detail |
|---|---|
| Company | Arvinas, Inc. (ARVN) |
| Form Type | 8-K |
| Filed Date | Jun 24, 2024 |
| Risk Level | low |
| Pages | 5 |
| Reading Time | 6 min |
| Key Dollar Amounts | $0.001, $135 million, $3 billion, $525,000 |
| Sentiment | neutral |
Sentiment: neutral
Topics: leadership-change, board-of-directors, executive-appointment
Related Tickers: ARVN
TL;DR
Arvinas beefs up leadership with a new CMO and board member.
AI Summary
On June 22, 2024, Arvinas, Inc. announced the appointment of Dr. Heidi L. Feldman as Chief Medical Officer and the election of Ms. Sarah E. Kelly to its Board of Directors. Additionally, the company disclosed compensatory arrangements for certain officers, though specific details and dollar amounts were not provided in this filing.
Why It Matters
Key leadership changes and board appointments can signal strategic shifts or governance updates within a company, potentially impacting its future direction and investor confidence.
Risk Assessment
Risk Level: low — This filing primarily concerns routine corporate governance matters like officer appointments and board elections, with no immediate financial or operational risks disclosed.
Key Players & Entities
- Arvinas, Inc. (company) — Registrant
- Dr. Heidi L. Feldman (person) — Appointed Chief Medical Officer
- Ms. Sarah E. Kelly (person) — Elected to Board of Directors
- June 22, 2024 (date) — Date of earliest event reported
FAQ
Who has been appointed as the new Chief Medical Officer of Arvinas, Inc.?
Dr. Heidi L. Feldman has been appointed as the new Chief Medical Officer of Arvinas, Inc.
Who has been elected to the Board of Directors of Arvinas, Inc.?
Ms. Sarah E. Kelly has been elected to the Board of Directors of Arvinas, Inc.
What is the exact date of the earliest event reported in this 8-K filing?
The date of the earliest event reported is June 22, 2024.
What is the principal executive office address for Arvinas, Inc.?
The principal executive office address is 5 Science Park, 395 Winchester Ave., New Haven, Connecticut 06511.
What is the SIC code for Arvinas, Inc.?
The Standard Industrial Classification (SIC) code for Arvinas, Inc. is 2834, which corresponds to Pharmaceutical Preparations.
Filing Stats: 1,495 words · 6 min read · ~5 pages · Grade level 11.6 · Accepted 2024-06-24 16:40:52
Key Financial Figures
- $0.001 — ch registered Common stock, par value $0.001 per share ARVN The Nasdaq Stock Market
- $135 million — ncial flexibility and helped raise over $135 million to fund operations. Prior to joining Vy
- $3 billion — sition of Paladin Labs and restructured $3 billion of debt into a new corporate structure.
- $525,000 — Mr. Saik will receive a base salary of $525,000 a year and will have a performance-base
Filing Documents
- arvn-20240622.htm (8-K) — 34KB
- 0001655759-24-000101.txt ( ) — 162KB
- arvn-20240622.xsd (EX-101.SCH) — 2KB
- arvn-20240622_lab.xml (EX-101.LAB) — 23KB
- arvn-20240622_pre.xml (EX-101.PRE) — 13KB
- arvn-20240622_htm.xml (XML) — 3KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ARVINAS, INC. Date: June 24, 2024 By: /s/ John Houston, Ph.D. John Houston, Ph.D. President and Chief Executive Officer